Ask complex regulatory questions and get comprehensive, source-cited answers in seconds. Built for the rigour life sciences demands.
Sponsor: [Sponsor Legal Name] · IP: [GLP-1 RA name] (SC once-weekly or oral once-daily) · Indication: Chronic weight management / T2DM · Regions: United States (FDA), Brazil (ANVISA + CEP/CONEP), Singapore (HSA + IRB)
Study Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of [IP] in Adults With [Obesity/Overweight OR T2DM], Conducted in the United States, Brazil, and Singapore.
This protocol is designed to align with three concurrent regulatory frameworks:
Form/Route: SC weekly injection or oral daily. Standard GLP-1 titration to reduce GI intolerance — start low for 4 weeks → uptitrate every 4 weeks. Dose reductions allowed per tolerability algorithm.
Placebo: Matched placebo (appearance, device/tablet, titration schedule).
Background SoC: Standardised lifestyle counseling across all arms with identical frequency/content. T2DM path: stable metformin allowed; rescue algorithm defined if persistent hyperglycaemia (FPG >270 mg/dL or HbA1c >10.5%).
Conduct under IND per 21 CFR §312.23. Informed consent per 21 CFR §50.20: "no investigator may involve a human being as a subject unless the investigator has obtained the legally effective informed consent."
fda.govANVISA RDC 9/2015 defines procedures for DDCM submission. Ethics via Plataforma Brasil — "base nacional e unificada de registros de pesquisas envolvendo seres humanos."
bvsms.saude.gov.brRegulated under the Health Products Act via Clinical Trial Authorisation (CTA) or Clinical Trial Notification (CTN) routes as applicable.
hsa.gov.sgPer FDA IND safety reporting requirements: unexpected serious suspected adverse reactions must be reported "as soon as possible but no later than within 15 calendar days"; unexpected fatal/life-threatening SUSARs within 7 calendar days. (fda.gov)
The letter claims your compounded veloratide-protection provisions veloratide protection provisions the letter cites similarly risk being characterized as impermissible de-facto FDCA enforcement the letter cites similarly risk being characterized as impermissible de facto FDCA enforcement when asserted by a private competitor.
Below is a more detailed breakdown, organized around the specific legal theories Nexion Therapeutics raises or implies.
"This database has proven to be an invaluable resource, offering reliable, well-curated information that greatly enhances decision-making and our communication with regulatory agencies and partners."
"Leaf AI is the most versatile, all-encompassing AI-enabled, regulatory tool on the market. It integrates data and information from publicly facing databases pertinent to all products regulated by FDA and other competent regulatory agencies across the globe. It is far more than regulatory compliance or intelligence: it was designed for product developers."
"This database has proven to be an invaluable resource, offering reliable, well-curated information that greatly enhances decision-making and our communication with regulatory agencies and partners."
We combine the expertise of former FDA leaders, regulatory lawyers, and consultants with powerful AI-driven platforms to deliver tailored solutions for pharmaceutical companies. We help you bring therapies to market faster, minimize compliance risks, and navigate FDA interactions with confidence.
We've built a comprehensive eCTD submission analysis platform that transforms how pharmaceutical companies prepare and review regulatory filings. Our AI-powered software analyses your entire submission, whether NDA, ANDA, IND, BLA, or 505(b)(2), in real time as it's being written, mapping every module and section directly against ICH CTD guidelines and FDA reviewer expectations.
We deliver AI-powered clinical trial management and Trial Master File software designed to modernise how sponsors and CROs run clinical studies. Our platform brings intelligent automation to every stage of trial operations — from site selection and study startup through monitoring, data management, and TMF completeness.
Member of the NVIDIA Connect Program
Every answer cited. Every source verified. Built for the people who can't afford to get it wrong.
Every claim linked to its original source — FDA databases, PubMed, ClinicalTrials.gov, EMA. Verify anything in one click.
Subject-matter-expert-in-the-loop validation. Built with former FDA counsel and regulatory professionals who understand what's at stake.
Comprehensive multi-source analysis that used to take days of manual research — delivered in under 30 seconds with full citations.
AI-powered document classification, gap analysis, and submission readiness scoring for electronic Common Technical Documents.
Global trial discovery, enrollment monitoring, competitive pipeline tracking, and protocol benchmarking across therapeutic areas.
Custom alerts for FDA approvals, warning letters, 483s, competitor activity, and regulatory changes across global jurisdictions.
We believe every day saved in the regulatory process is a day a treatment reaches a patient sooner. Leaf AI exists to remove the friction between discovery and approval — giving regulatory teams the intelligence they need to move with confidence.
Built by a team at the intersection of AI engineering and regulatory science, we're not just building tools. We're building the infrastructure life science companies need to navigate an increasingly complex global regulatory landscape.
Read our full missionFormer FDA counsel, AI engineers, and data scientists — united by the mission to modernise regulatory intelligence.
Mark is a seasoned FDA regulatory attorney and former counsel at the U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER). With more than two decades of experience spanning government, industry, and private practice, he has advised global pharmaceutical companies, trade associations, and emerging innovators on complex regulatory, compliance, and international market issues. Based in Kentucky, Mark is the founder of White Oak AI Law, where he focuses on the intersection of life sciences and artificial intelligence. As both an advisor and investor in our company, he brings unparalleled insight into FDA regulatory pathways, compliance strategy, and the evolving landscape of biopharma innovation.
Rohan has a background in computer science and economics, with a focus on building AI systems that improve efficiency across life sciences while maintaining accuracy and precision. Passionate about shortening development timelines through automated research so treatments reach patients faster.
Alexander brings a strong foundation in mathematics and computer science to solving some of the most complex challenges in life sciences and technology. Passionate about applying AI to uncover insights from difficult-to-access data and has built tools that help leaders make sharper, faster decisions.
Pipeline & portfolio analysis covering therapeutic strategy and competitive positioning.
In-depth forecast of drug pricing, supply chains, and competitive positioning.
Balancing aging blockbuster biologics with new growth drivers and an ambitious pipeline.
Definitions sourced from FDA guidance documents, ICH guidelines, and federal regulations.
An FDA Form 483 is issued by the U.S. Food and Drug Administration to document observations of potential GMP violations identified during an inspection of a pharmaceutical manufacturing facility. Companies typically have 15 business days to respond with a corrective action plan. See our FDA 483 trend analysis for deeper enforcement insights.
The FDA issues a Warning Letter after determining that a company has significant violations of the Federal Food, Drug, and Cosmetic Act. The letter outlines regulatory concerns and requests corrective action within a specified timeframe, typically 15 working days. Failure to respond may result in further enforcement such as import alerts, injunctions, or consent decrees.
A Complete Response Letter is issued by the FDA when a review cycle for a drug application (NDA, ANDA, or BLA) is complete but the application is not ready for approval. The CRL describes the deficiencies that must be addressed before approval can be granted, and applicants may resubmit, request a hearing, or withdraw the application.
A 505(b)(2) is an FDA regulatory pathway that allows pharmaceutical companies to rely on the agency's previous findings of safety and efficacy for an already-approved drug. This pathway is commonly used for modified formulations, new dosage forms, new indications, and drug repurposing — significantly reducing clinical trial requirements and time to market.
Current Good Manufacturing Practice (CGMP) refers to the FDA regulations under 21 CFR Parts 210 and 211 that govern the design, monitoring, and control of pharmaceutical manufacturing processes and facilities. CGMP compliance ensures that drug products meet quality standards for identity, strength, purity, and composition.
The electronic Common Technical Document (eCTD) is the internationally agreed format for submitting regulatory applications to agencies including the FDA and EMA. It organises all quality, nonclinical, and clinical data into a standardised five-module structure required for NDAs, ANDAs, INDs, and BLAs. Leaf Intelligence provides AI-powered eCTD analysis to check submission completeness in real time.
Unlike standard literature databases, Leaf Intelligence simultaneously searches FDA databases, PubMed, ClinicalTrials.gov, EMA records, and ICH guidance documents — then synthesises a comprehensive answer with every claim linked to its original source. It is purpose-built for the rigour that regulatory professionals require.
Leaf Intelligence handles questions across approval pathways (505(b)(2), NDA, ANDA, BLA), FDA enforcement analytics (483s, Warning Letters, consent decrees), competitive intelligence, clinical trial analysis, eCTD submission readiness, and ICH guideline interpretation. See our product demo for examples.
Yes. All uploaded documents and queries are encrypted in transit and at rest. We do not use client data to train models. Our infrastructure runs on enterprise-grade cloud infrastructure with SOC 2 controls in place. Review our Privacy Policy for full details.
An FDA 483 documents inspection observations at the time of an inspection, while a Warning Letter is a formal enforcement action issued after the FDA determines that violations identified in a 483 were not adequately addressed. Leaf Intelligence tracks both in real time across all FDA-regulated facilities.
You can book a demo with our team to see the platform in action, or try Leaf AI directly. We offer tailored onboarding for regulatory affairs, clinical operations, and competitive intelligence teams.
Leaf Intelligence aggregates and analyses data from authoritative regulatory and scientific sources, including FDA Warning Letters database, FDA 483 inspection observations, Federal Register publications, ICH Guidance documents (E6(R2), E8, E9, M4), ClinicalTrials.gov registry, PubMed and MEDLINE, EMA European Public Assessment Reports, and patent and exclusivity databases.
Learn more about our methodology →